Percepio announces the successful closing of a 22 MSEK (2.3 MUSD) Series A funding round led by Fairpoint Capital AB. The investment is intended to scale up operations and accelerate the product development roadmap, with a focus on embedded software and Internet of Things (IoT).
Percepio is pioneering the area of visual trace diagnostics, which has a great potential for helping developers cope with runtime complexity. Percepio is uniquely positioned to provide visual trace diagnostics to a broad range of software organizations. The funding will allow the company to reach many new customers and help them build amazing products, on time and on budget.
STOAF PORTFOLIO COMPANY ILYA PHARMA AWARDED €5.3M FROM EIC ACCELERATOR TO FAST TRACK PHASE II STUDY OF FIRST-IN-CLASS ILP100 ADVANCE THERAPY FOR WOUND TREATMENT IN PEOPLE WITH DIABETES
Ilya Pharma, a clinical stage biopharma company developing novel chemokine gene therapies with its ILP-technology platform, today announced that it has secured a total of Euros 5.3 million in funding from the European Innovation Council (EIC) Accelerator program of blended financing.
The funds will enable Ilya Pharma to accelerate a Phase II Trial of its lead drug candidate ILP100 which has the potential to heal problematic non-healing wounds in diabetes, potentially up to 80% faster, and deliver savings to overburdened healthcare systems of Euros 6 billion annually. The EIC Accelerator (SME Instrument) award supports small and medium-sized companies with breakthrough innovations and the potential to create new markets or redefine existing ones globally. Less than 5% of applicants selected for the prestigious award succeed, but Ilya Pharma joins an even more select group by having now won for a second time – the first in 2018 also for ILP100 developments in a first in human clinical trial.
Stoaf III SciTech, Almi Invest and others invest 4,8 MSEK in VOC Diagnostics. It is part-financing of a further development and testing of its unique sensor-equipped instrument used for diagnosing ovarian cancer.
VOC Diagnostics has recently employed Linda Spahiu as its CEO. The financing is to be used to complete the instrument for clinical use, clinical studies and CE certifcation.
"VOC's method and diagnostic instrument provides a huge potential to contribute to improved health for patients with ovarian cancer, both in Sweden and globally. Stoaf's ambition is to contribute with both capital and competence to the success of the company and to a better life to the affected women", says Claes Post, responsible General Partner for Stoaf's Life Science investments.
Cliff Higgerson, Palo Alto, CA, previous General Partner in several VC-funds in Silicon Valley invests in Stoaf III SciTech and accepts to become its Senior Advisor.
"We are very happy to see the confidence of a Silicon Valley heavyweight such as Cliff shows for Stoaf by investing in our third fund" says the fund´s CEO and General Partner P A Wärn. "He will via his long and successful experience as General Partner in ComVentures and Vanguard Ventures contribute valuable competence to our GP team".
EmbeDL, Gothenburg is a spin-off from a big EU-financed collaborative R&D project with Chalmers University. It has a unique technology for testing sophisticated components used by the automotive industry among other engineering industries. Co-investors are Almi Invest and Chalmers Ventures.
STOAF III SciTech and Almi Invest invest in a first tranche 3 MSEK each in Limina, Stockholm. It has developed the asset management market´s first complete cloudbased asset management system for hedge and mutual funds. In the same financing round of 15 MSEK participates also Vidici II and Justin Wheatley – the founder of his recently sold listed StatPro participated among other participants.
- LImina has a great opportunity to accelerate both sales and the continued development of the functionality of its system Captron. The company has the potential to reach a leading global position says P A Wärn, General Partner at STOAF who will take a seat at the board of directors.